awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35169166-3B1B1438-4E95-4C37-9EC5-CDD12E06DD15
Q35169166-3B1B1438-4E95-4C37-9EC5-CDD12E06DD15
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35169166-3B1B1438-4E95-4C37-9EC5-CDD12E06DD15
Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?
P2860
Q35169166-3B1B1438-4E95-4C37-9EC5-CDD12E06DD15
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35169166-3B1B1438-4E95-4C37-9EC5-CDD12E06DD15
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
efcd78df4254291f355715e0c6bfab4b4b353db6
P2860
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.